GQ-1001 is under clinical development by GeneQuantum Healthcare Suzhou and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GQ-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GQ-1001 overview

GQ-1001 is under development for the treatment of HER2 high breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma and other solid tumors. It is administered through intravenous route. The drug candidate is an antibody drug conjugate (human anti-ErbB2/Her2 antibody-maytansinoid derivative conjugate). The therapeutic candidate is developed based on Ligase Dependent Conjugation (LDC) technology. The drug candidate acts by targeting HER2.

GeneQuantum Healthcare Suzhou overview

GeneQuantum Healthcare Suzhou (GeneQuantum Healthcare) is a biopharmaceutical company developing bioconjugate medicines to treat cancer. It is investigating GQ1001 drug against gastric, breast cancers and other solid tumors caused due to high levels of HER2 (human epidermal growth factor receptor 2) and GQ1003 to treat NSCLC (non-small cell lung cancer) and TNBC (triple-negative breast cancer). The company is also evaluating GQ1005 for the treatment of HER2 low and medium gastric and breast cancer, GQ1007 and GQ1010 drugs targeting immune cold tumors. GeneQuantum Healthcare utilizes Ligase dependent conjugation (iLDC) technology platform to develop treatments and deliver drugs. It partners with biotechnology companies, academia laboratories and other global corporations to create bio-conjugate drugs and technologies. GeneQuantum Healthcare is headquartered in Suzhou, Jiangsu, China.

For a complete picture of GQ-1001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.